Frazier & Co. Moves Into Technology Investing
This article was originally published in Start Up
Frazier & Co.'s recent launch of Frazier Technology Ventures (FTV), a new technology fund that will apportion part of its portfolio to e-health/bioinformatic companies seems, at first blush, to come at a bit of an odd time. The volatility of the tech sector has many VCs reexamining their positions in that arena, with e-health financings particularly hard hit. Frazier & Co.'s move is also contrary to the general trend of VC firms choosing to specialize in either e-health or traditional health care investing. A number of health care firms, like Oak, Sequoia and Accel dropped health care entirely last year during the e-health boom. And Brentwood Ventures spun out separate IT and health care groups. But, according to Frazier & Co.'s management, their timing was just right and reflects both patience and careful planning. Moreover, they emphasize that the new fund, while within the Frazier & Company infrastructure, will, in fact, be invested independently by a group of Information Technology specialists.
You may also be interested in...
Earlybird hopes to capitalize on the convergence of information technologies with health care. It sees these two sectors not as separate strands with fundamentally different investment strategies, but rather as areas whose increasing overlap presents a new pool of companies needing support with experience in both businesses, and, the contend, bi-continental reach.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.